Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management

Annals of Gastroenterology

Volumn 25, Issue 2, 2012, Pages 106-118

  Boussios, Stergios ^a   Pentheroudakis, George ^a   Katsanos, Konstantinos ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer; Chemotherapy; Gastrointestinal toxicity

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; GRANISETRON; IFOSFAMIDE; IMATINIB; LOPERAMIDE; METHOTREXATE; NITROSOUREA; OCTREOTIDE; ONDANSETRON; OXALIPLATIN; PROCARBAZINE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TROPISETRON; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ANUS DISEASE; ANUS INFLAMMATION; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY FAT; BONE MARROW SUPPRESSION; CELL DAMAGE; CELL REGENERATION; CHOLESTASIS; CLINICAL FEATURE; COLITIS; COLON ULCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; ESOPHAGITIS; ESOPHAGUS ULCER; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GLOSSODYNIA; GRANULOMATOUS HEPATITIS; HEMOPTYSIS; HEMORRHAGIC COLITIS; HEMORRHAGIC GASTRITIS; HEMORRHOID; HEPATITIS; HICCUP; HUMAN; HYPERBILIRUBINEMIA; ILEUS; INCIDENCE; INTERPERSONAL COMMUNICATION; INTESTINAL FIBROSIS; INTESTINE NECROSIS; INTESTINE ULCER; KIDNEY DYSFUNCTION; LACTATE BLOOD LEVEL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER SINUSOIDAL DILATATION; LIVER VEIN THROMBOSIS; MEDICAL DECISION MAKING; MELENA; MOUTH INFLAMMATION; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PANCREATITIS; PARALYTIC ILEUS; PATIENT CARE; PHARYNGITIS; PROCTITIS; PROTEIN DEPLETION; RECTUM HEMORRHAGE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH ULCER; STOMATITIS; TENESMUS; THERAPY DELAY; TONGUE DISEASE; TONGUE HYPERPIGMENTATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; XEROSTOMIA;

EID: 84859878717     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Bonaventura A. Complications of cytotoxic therapy. Australian Prescriber 1995;18:65-67.
2. Rubenstein E, Peterson D, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-2046.
3. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001;1:370-377.
4. Li Z, Ibrahim NK, Wathen JK, et al. Colitis in patients with breast carcinoma treated with Taxane-based chemotherapy. Cancer 2004;101:1508-1513.
5. Jamieson ER, Lippard SJ. Structure, recognition and processing of Cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498.
6. Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: Possible reversal by N-Acetylcysteine treatment. J Am Soc Nephrol 1997;8:1640-1645.
7. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
8. Markman M, Zanotti K, Webster K, Belinson J, Rose P. Toxicity associated with carboplatin/paclitaxel/irinotecan use in advanced ovarian cancer: preliminary analysis. Oncology (Williston Park) 2003;17:34-35.
9. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;2:11-20.
10. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Let 2005;10:631-647.
11. Parnham MJ, Bruinvels J. Milestones in Drug Therapy. In: Pinelo HM and Smorenburt CH (editors): Drugs affecting growth of tumours. Birkhäuser Verlag: Basel, Switzerland;2006:19-81.
12. Bardos TJ. Topics in current chemistry. In: Boschke FL (editor): Antimetabolites: Molecular design and mode of action. Springer Verlag: Berlin; 1974:63-98.
13. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338.
14. Rougier P, Paillot B, Laplanche A, et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer 1997;33:1789-1793.
15. McCollum AD, Catalano P, Haller D. Outcomes and toxicity in African American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002;94:1160-1167.
16. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
17. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
18. Salser JS, Balis ME. The mechanism of action of 6 Mercaptopurine. I. Biochemical effects. Cancer Res 1965;25:539-543.
19. Katsanos KH, Tsianos EV. Azathioprine/6-mercaptopurine toxicity: the role of the TPMT gene. Ann Gastroenterol 2007;20:251-264.
20. Yamauchi T, Negoro E, Kishi S, et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/ cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009;77:1780-1786.
21. Stentoft J. The toxicity of cytarabine. Drug Saf 1990;5:7-27.
22. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
23. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998;114:1779-1781.
24. Hryniuk WM. The Mechanism of action of Methotrexate in cultured L5178Y leukemia cells. Cancer Res 1975;35:1085-1092.
25. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
26. Schiemann U, Kellner H. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol 2002;40:937-943.
27. Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutation Res 1996;355:13-40.
28. Solimando DA. Mechlorethamine and procarbazine. Hospital Pharmacy 1998;33:1300-1304.
29. Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994;12:764-768.
30. Bank BB. Studies of chlorambucil-DNA adducts. Biochem Pharmacol 1992;44:571-575.
31. Electronic Medicines Compendium (5th Edition) http://emc. vhn.net/ Dec 2005.
32. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 2004;65:1278-1285.
33. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982;9:75-83.
34. Haubitz M. Acute and long-term toxicity of cyclophosphamide. Tx Med 2007;19:26-31.
35. Watanabe Y, Etoh M, Koike E, Mizuno Y, Wang WM, Hoshiai H. Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol 2010;15:468-471.
36. Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970;3:588.
37. Klastersky J. Side effects of ifosfamide. Oncology 2003;65:7-10.
38. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer 2008;50:347-351.
39. Einhorn LH, Loehrer PJ. Ifosfamide chemotherapy for pancreatic carcinoma. Cancer Chemother Pharmacol 1986;18:S51-S54.
40. Katz ME, Glick JH. Nitrosoureas: a reappraisal of clinical trials. Cancer Clin Trials 1979;2:297-316.
41. De Vita VT, Carbone PP, Owens AH Jr, Gold GL, Krant MJ, Edmonson J. Clinical trials with 1,3-bis (2-chloroethyl)-nitrosourea, NSC-409962. Cancer Res 1965;25:1876-1881.
42. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990;1:5-13.
43. Hanna WT, Krauss S, Regester RF, Murphy WM. Renal disease after mitomycin c therapy. Cancer 1981;48:2583-2588.
44. Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemother Pharmacol 1990;26:457-460.
45. Erichsen C, Jonsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 1984;27:268-270.
46. Deleve LD. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. J Pharmacol Exp Ther 1994;268:1261-1270.
47. Cubeddu LX, O'Connor DT, Hoffmann I, Parmer RJ. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer 1995;72:1033-1038.
48. Tweedie DJ, Fernandez D, Spearman ME, Feldhoff RC, Prough RA. Metabolism of azoxy derivatives of procarbazine by aldehyde dehydrogenase and xanthine oxidase. Drug Metab Dispos 1991;19:793-803.
49. Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag 2007;3:213-224.
50. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
51. Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits calcium-dependent chloride secretion in T84 human colonic epithelial cells. Am J Physiol Cell Physiol 1996;271:914-922.
52. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006;80:136-145.
53. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell cancer. J Clin Oncol (Meeting Abstracts) 2005;23(Suppl 16):LBA4510.
54. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
55. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-174.
56. Van Glabbeke M, Verweij J, Casali PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTCISG-AGITG). Eur J Cancer 2006;42:2277-2285.
57. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
58. Papandreou CN, Daliani DD, Nix D, et al. Phase I of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-2121.
59. Aghajanian C, Soignet S, Dizon DS, et al. A phase I of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-2511.
60. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 2006;17:423-427.
61. Suzuki T, Sakai H, Takeguchi N. Thromboxane A(2)-mediated Cl(-) secretion induced by platelet-activating factor in isolated rat colon. Eur J Pharmacol 2000;400:297-303.
62. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-1783.
63. Burger H, Van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4:747-752.
64. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-281.
65. Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;18:785-787.
66. Cross TJS, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81:189-192.
67. Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002;16:2160-2161.
68. Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005;23:8531-8533.
69. Kikuchi S, Muroi K, Takahashi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004;45:2349-2351.
70. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17:978-979.
71. Dhalluin-Venier V, Besson C, Dimet S, Thirot-Bibault A, Tchernia G, Buffet C. Imatinib mesylate induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2006;18:1235-1237.
72. Lin NU, Sarantopoulos S, Stone JR, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 2003;102:3455-3456.
73. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.
74. Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91(Suppl 6):ECR27.
75. Kozloff M, Cohn A, Christiansen N, et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy for metastatic colorectal cancer: updated results from a large observational study in the US (BRiTE). Gastrointestinal Cancers Symposium 2006 [abstract #247].
76. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006;64:1295-1298.
77. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side effects of cancer chemotherapy. Eur J Cancer Oncology 1983;19:203-208.
78. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729-764.
79. Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-728.
80. Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992;19(Suppl 10):1-8.
81. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatininduced emesis: A double-blind multicenter randomized crossover study comparing ondansetron plus dexamethasone. J Clin Onc 1991;9:675-678.
82. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: Evidence based clinical practice guidelines. J Clin Oncol 1999;17:2971-2994.
83. Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomised study. Eur J Cancer 1993;29A:1669-1672.
84. Engelking C, Rutledge DN, Ippoliti C, Neumann J, Hogan CM. Cancer related diarrhea: a neglected cause of cancer-related symptom distress. Oncol Nurs Forum 1998;25:859-860.
85. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996;32A(Suppl 3):S24-S31.
86. Stern J, Ippoliti C. Management of acute cancer treatment-induced diarrhea. Semin Oncol Nurs 2003;19(4 Suppl 3):11-16.
87. Jansman FG, Sleijfer DT, De Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001;24:353-367.
88. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(Suppl 9):2026-2046.
89. Sharma R, Tobin P, Clarke SJ. Management of chemotherapyinduced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
90. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539.
91. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006;14:890-900.
92. Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am 1987;71:303-311.
93. King PD, Perry MC. Hepatotoxicity of Chemotherapy. Oncologist 2001;6:162-176.
94. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-485.
95. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000;14:193-212.
96. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996;31:47-64.
97. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapyinduced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):232-243.
98. Benson III AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. JCO 2004;22:2918-2926.
99. Elting LS, Keefe DMK, Sonis ST. Treatment induced gastrointestinal toxicity in patients with cancer. ASCO 2005:117-123.